# Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

> **NCT02093962** · PHASE2 · TERMINATED · sponsor: **ImmunoGenesis** · enrollment: 265 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TH-302 combination with pemetrexed
- **DRUG:** Matched placebo in combination with pemetrexed

## Key facts

- **NCT ID:** NCT02093962
- **Lead sponsor:** ImmunoGenesis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 265 (ACTUAL)
- **Why stopped:** At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093962, "Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02093962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*